Last updated on August 2019

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer


Brief description of study

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.

SECONDARY OBJECTIVES:

I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of predefined subsequent cardiac events in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.

II. To evaluate if prophylactic carvedilol compared with no intervention results in a longer time to first interruption of trastuzumab?based HER-2 targeted therapy due to either cardiac dysfunction or events.

III. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction OR events in this population.

IV. To establish and prospectively collect a predefined panel of baseline core cardiovascular measures and develop a predictive model of cardiac dysfunction.

V. To evaluate the rate of cardiac dysfunction in an observational arm consisting of individuals otherwise eligible for the study except for use of beta blockers, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitors for other medical reasons.

TERTIARY OBJECTIVES:

I. To evaluate the isoleucine (lle) 655 valine (Val) and and alanine (Ala)ll70 proline (Pro) single nucleotide polymorphisms (SNPs) of the HER-2 gene as a predictive biomarker of study-defined cardiac dysfunction.

II. To evaluate plasma neuregulin-1 at baseline and over study time as a predictive biomarker of study-defined cardiac dysfunction.

III. To evaluate the feasibility of performing serial left ventricular strain in a National Clinical Trials Network (NCTN) group setting, with the goal of 75% of patients contributing both a baseline and at least one follow-up strain measurement.

IV. To bank blood for future translational medicine studies such as brain natriuretic peptide (BNP), additional SNPs, and high sensitivity troponin.

OUTLINE: Patients are randomized to 1 of 2 arms. Patients taking beta blocker, ARB, or ACE inhibitor at registration are assigned to Arm III.

ARM I: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol orally (PO) twice daily (BID). Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.

ARM II: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.

ARM III: Patients undergo observation for up to 108 weeks.

After completion of study, patients are followed up for up to 108 weeks.

Clinical Study Identifier: NCT03418961

Find a site near you

Start Over

Decatur Memorial Hospital

Decatur, IL United States
  Connect »

Geauga Hospital

Chardon, OH United States
  Connect »

Saint Francis Medical Center

Cape Girardeau, MO United States
  Connect »

Assarian Cancer Center

Novi, MI United States
  Connect »

Reid Health

Richmond, IN United States
  Connect »

Olathe Medical Center

Olathe, KS United States
  Connect »

Mercy Health Saint Mary's

Grand Rapids, MI United States
  Connect »

City of Hope Mission Hills

Mission Hills, CA United States
  Connect »

City of Hope Rancho Cucamonga

Rancho Cucamonga, CA United States
  Connect »

City of Hope South Pasadena

South Pasadena, CA United States
  Connect »

Beebe Health Campus

Rehoboth Beach, DE United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Cleveland Clinic-Weston

Weston, FL United States
  Connect »

Northside Hospital

Atlanta, GA United States
  Connect »

Mercy Medical Center-West Lakes

West Des Moines, IA United States
  Connect »

Mary Bird Perkins Cancer Center

Baton Rouge, LA United States
  Connect »

Woman's Hospital

Baton Rouge, LA United States
  Connect »

Winchester Hospital

Winchester, MA United States
  Connect »

Saint Joseph Mercy Hospital

Ann Arbor, MI United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

McLaren-Greater Lansing

Lansing, MI United States
  Connect »

McLaren Cancer Institute-Macomb

Mount Clemens, MI United States
  Connect »

Henry Ford West Bloomfield Hospital

West Bloomfield, MI United States
  Connect »

Hennepin County Medical Center

Minneapolis, MN United States
  Connect »

Monticello Cancer Center

Monticello, MN United States
  Connect »

United Hospital

Saint Paul, MN United States
  Connect »

Capital Region Southwest Campus

Jefferson City, MO United States
  Connect »

CHI Health Saint Francis

Grand Island, NE United States
  Connect »

Aultman Health Foundation

Canton, OH United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

Dayton Physicians LLC-Atrium

Franklin, OH United States
  Connect »

Hillcrest Hospital Cancer Center

Mayfield Heights, OH United States
  Connect »

North Coast Cancer Care

Sandusky, OH United States
  Connect »

South Pointe Hospital

Warrensville Heights, OH United States
  Connect »

UHHS-Westlake Medical Center

Westlake, OH United States
  Connect »

Kaiser Permanente Northwest

Portland, OR United States
  Connect »

University Medical Center

Lubbock, TX United States
  Connect »